| Malignant neoplasm of breast
Halaven vs Lynparza
Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of breast.Deep comparison between: Halaven vs Lynparza with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLynparza has a higher rate of injection site reactions vs Halaven based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lynparza but not Halaven, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Halaven
Lynparza
At A Glance
IV infusion
Days 1 and 8 of a 21-day cycle
Microtubule dynamics inhibitor
Oral
Twice daily
PARP inhibitor
Indications
- Malignant neoplasm of breast
- Sarcoma
- Carcinoma, Ovarian Epithelial
- Fallopian Tube Carcinoma
- Primary Peritoneal Cancer
- Malignant neoplasm of breast
- Adenocarcinoma of pancreas
- Hormone refractory prostate cancer
Dosing
Malignant neoplasm of breast, Sarcoma 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle; reduce to 1.1 mg/m2 for mild hepatic impairment (Child-Pugh A) or moderate/severe renal impairment (CLcr 15-49 mL/min); reduce to 0.7 mg/m2 for moderate hepatic impairment (Child-Pugh B).
Carcinoma, Ovarian Epithelial, Fallopian Tube Carcinoma, Primary Peritoneal Cancer (first-line BRCAm maintenance) 300 mg orally twice daily; continue until disease progression, unacceptable toxicity, or completion of 2 years of treatment.
Carcinoma, Ovarian Epithelial, Fallopian Tube Carcinoma, Primary Peritoneal Cancer (first-line HRD-positive, + bevacizumab) 300 mg orally twice daily with bevacizumab 15 mg/kg every 3 weeks; continue until disease progression, unacceptable toxicity, or completion of 2 years of treatment.
Carcinoma, Ovarian Epithelial, Fallopian Tube Carcinoma, Primary Peritoneal Cancer (recurrent BRCAm maintenance) 300 mg orally twice daily; continue until disease progression or unacceptable toxicity.
Malignant neoplasm of breast (adjuvant, gBRCAm HER2-negative high risk early) 300 mg orally twice daily for a total of 1 year, or until disease recurrence or unacceptable toxicity.
Malignant neoplasm of breast (metastatic, gBRCAm HER2-negative) 300 mg orally twice daily; continue until disease progression or unacceptable toxicity.
Adenocarcinoma of pancreas 300 mg orally twice daily; continue until disease progression or unacceptable toxicity.
Hormone refractory prostate cancer (HRR gene-mutated mCRPC, monotherapy) 300 mg orally twice daily with concurrent GnRH analog or prior bilateral orchiectomy; continue until disease progression or unacceptable toxicity.
Hormone refractory prostate cancer (BRCAm mCRPC, + abiraterone) 300 mg orally twice daily with abiraterone 1000 mg once daily and prednisone or prednisolone 5 mg twice daily; continue until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=25%) - Metastatic breast cancer Neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, constipation
Most common (>=25%) - Liposarcoma and leiomyosarcoma Fatigue, nausea, alopecia, constipation, peripheral neuropathy, abdominal pain, pyrexia
Serious Febrile neutropenia, neutropenia
Postmarketing Lymphopenia, pancreatitis, hepatotoxicity, drug hypersensitivity, pneumonia, sepsis/neutropenic sepsis, interstitial lung disease, pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis
Most common (>=10%) nausea, fatigue, anemia, vomiting, diarrhea, decreased appetite, headache, dysgeusia, cough, neutropenia, dyspnea, dizziness, dyspepsia, leukopenia, thrombocytopenia
Serious myelodysplastic syndrome, acute myeloid leukemia, pneumonitis, venous thromboembolism, hepatotoxicity including drug-induced liver injury
Postmarketing drug-induced liver injury, hypersensitivity including angioedema, erythema nodosum, rash, dermatitis
Pharmacology
Eribulin mesylate is a microtubule dynamics inhibitor that inhibits the growth phase of microtubules, sequesters tubulin into nonproductive aggregates, and exerts antimitotic effects via G2/M cell-cycle block and disruption of mitotic spindles, ultimately leading to apoptotic cell death after prolonged mitotic blockage.
Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes (PARP1, PARP2, PARP3) involved in DNA transcription and repair; cytotoxicity occurs through inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes, with enhanced activity in tumor cells harboring deficiencies in BRCA1/2, ATM, or other homologous recombination repair (HRR) genes.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Halaven
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (0/12)
Lynparza
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Halaven
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Lynparza
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Halaven
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Lynparza
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0/fillfill
Lynparza Patient Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
HalavenView full Halaven profile
LynparzaView full Lynparza profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.